HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab
- 1 February 2018
- journal article
- research article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 18 (2) , e143-e146
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapyAIDS, 2016
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's LymphomaNew England Journal of Medicine, 2015
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated MalignanciesClinical Cancer Research, 2013
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted TherapyClinical Cancer Research, 2012
- EBV AND HIV-RELATED LYMPHOMAMediterranean Journal of Hematology and Infectious Diseases, 2009
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunctionNature Medicine, 2006
- PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progressionNature, 2006
- HIV-Associated Hodgkin Lymphoma : A Clinicopathologic and Immunophenotypic Study of 45 CasesAmerican Journal of Clinical Pathology, 2004
- HIV-Associated Hodgkin LymphomaAmerican Journal of Clinical Pathology, 2004